$BTCY
BIOTRICITY INC. Stock $btcy

$btcy Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223028510 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$2.891M	$3.021M	$2.056M
YoY Change	21.41%	46.92%	16.55%
Cost Of Revenue	$892.0K	$1.104M	$830.9K
YoY Change	-18.99%	32.87%	39.88%
Gross Profit	$1.999M	$1.917M	$1.225M
YoY Change	56.16%	56.45%	4.7%
Gross Profit Margin	69.15%	63.45%	59.59%
Selling, General & Admin	$3.487M	$3.520M	$4.850M
YoY Change	-28.22%	-27.41%	46.16%
% of Gross Profit	174.43%	183.66%	395.84%
Research & Development	$697.6K	$713.0K	$821.2K
YoY Change	-15.84%	-13.18%	39.42%
% of Gross Profit	34.89%	37.2%	67.03%
Depreciation & Amortization	$1.489K	$1.489K	$1.489K
YoY Change	0.0%	0.0%
% of Gross Profit	0.07%	0.08%	0.12%
Operating Expenses	$4.185M	$4.233M	$5.702M
YoY Change	-26.74%	-25.76%	36.66%
Operating Profit	-$2.186M	-$2.316M	-$4.477M
YoY Change	-50.69%	-48.26%	49.11%
Interest Expense	$753.3K	$660.5K	-$81.48K
YoY Change	-1090.23%	-910.64%	-96.87%
% of Operating Profit
Other Income/Expense, Net	-$143.4K	$13.44K
YoY Change	-5059.53%
Pretax Income	-$3.691M	-$3.413M	-$4.776M
YoY Change	-21.35%	-28.54%	-15.56%
Income Tax
% Of Pretax Income
Net Earnings	-$3.691M	-$3.413M	-$4.776M
YoY Change	-21.35%	-28.54%	-15.56%
Net Earnings / Revenue	-127.65%	-112.98%	-232.3%
Basic Earnings Per Share	-$0.44	-$0.07	-$0.10
Diluted Earnings Per Share	-$0.44	-$0.07	-$92.85K
COMMON SHARES
Basic Shares Outstanding	8.321M shares	51.05M shares	51.44M shares
Diluted Shares Outstanding	8.796M shares	52.51M shares	51.44M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.200M	$51.43K	$7.208M
YoY Change	-51.96%	-99.29%	3475.56%
Cash & Equivalents	$1.200M	$51.43K	$7.208M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$2.128M	$2.216M	$1.431M
Prepaid Expenses
Receivables	$1.610M	$1.513M	$1.827M
Other Receivables	$240.0K	$620.9K	$380.6K
Total Short-Term Assets	$5.178M	$4.401M	$10.85M
YoY Change	-23.31%	-59.43%	295.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$18.53K	$20.02K	$25.97K
YoY Change	-24.32%	-22.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.646M	$1.743M	$1.303M
YoY Change	26.46%	33.79%	5648.3%
TOTAL ASSETS
Total Short-Term Assets	$5.178M	$4.401M	$10.85M
Total Long-Term Assets	$1.646M	$1.743M	$1.303M
Total Assets	$6.824M	$6.144M	$12.15M
YoY Change	-15.26%	-49.43%	339.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.530M	$4.174M	$1.458M
YoY Change	269.29%	186.27%	13.64%
Accrued Expenses	$2.120M	$2.390M	$1.243M
YoY Change	50.45%	92.21%	-25.91%
Deferred Revenue
YoY Change
Short-Term Debt	$6.720M	$5.600M	$1.238M
YoY Change	490.51%	352.35%	-77.87%
Long-Term Debt Due	$1.200M	$600.0K
YoY Change
Total Short-Term Liabilities	$17.82M	$15.10M	$4.577M
YoY Change	306.13%	229.82%	-62.75%
LONG-TERM LIABILITIES
Long-Term Debt	$11.95M	$12.50M	$12.53M
YoY Change	-5.04%	-0.26%	1339.31%
Other Long-Term Liabilities	$2.520M	$1.958M	$1.599M
YoY Change	47.93%	22.42%	674.31%
Total Long-Term Liabilities	$14.47M	$14.46M	$14.13M
YoY Change	1.27%	2.3%	1211.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.82M	$15.10M	$4.577M
Total Long-Term Liabilities	$14.47M	$14.46M	$14.13M
Total Liabilities	$32.30M	$29.56M	$18.71M
YoY Change	72.92%	57.97%	39.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$120.1M	-$116.2M	-$98.06M
YoY Change	16.64%	18.47%
Common Stock	$8.811K	$52.51K	$51.69K
YoY Change	-83.02%	1.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$26.73M	-$23.41M	-$6.560M
YoY Change
Total Liabilities & Shareholders Equity	$6.824M	$6.144M	$12.15M
YoY Change	-15.26%	-49.43%	339.05%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$3.691M	-$3.413M	-$4.776M
YoY Change	-21.35%	-28.54%	-15.56%
Depreciation, Depletion And Amortization	$1.489K	$1.489K	$1.489K
YoY Change	0.0%	0.0%
Cash From Operating Activities	-$2.390M	-$1.832M	-$4.039M
YoY Change	-46.3%	-54.64%	50.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.430M	$1.329M	-$833.2K
YoY Change	-1357.42%	-259.52%	-243.39%
NET CHANGE
Cash From Operating Activities	-2.390M	-$1.832M	-$4.039M
Cash From Investing Activities
Cash From Financing Activities	3.430M	$1.329M	-$833.2K
Net Change In Cash	1.040M	-$503.0K	-$4.859M
YoY Change	-122.02%	-89.65%	142.95%
FREE CASH FLOW
Cash From Operating Activities	-$2.390M	-$1.832M	-$4.039M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001630113
CY2023Q2	dei	Amendment Flag AmendmentFlag	false
CY2023Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q1	BTCY	Term Loan Current TermLoanCurrent		usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2023Q2	BTCY	Issuance Of Warrants For Services IssuanceOfWarrantsForServices		usd
CY2023Q2	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock		usd
CY2023Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022Q2	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2022Q2	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
CY2023Q2	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q2	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues		usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues		usd
CY2023Q2	BTCY	Reduction Due To Preferred Shares Redeemed ReductionDueToPreferredSharesRedeemed		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023Q2	BTCY	Operating Lease Right Of Use Asset New Leases OperatingLeaseRightOfUseAssetNewLeases		usd
CY2022Q2	BTCY	Operating Lease Right Of Use Asset New Leases OperatingLeaseRightOfUseAssetNewLeases		usd
CY2023Q2	BTCY	Operating Lease New Leases OperatingLeaseNewLeases		usd
CY2022Q2	BTCY	Operating Lease New Leases OperatingLeaseNewLeases		usd
CY2023Q2	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions		usd
CY2023Q2	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals		usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1		usd
CY2023Q2	dei	Document Type DocumentType	10-Q
CY2023Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q2	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q2	dei	Entity File Number EntityFileNumber	000-40761
CY2023Q2	dei	Entity Registrant Name EntityRegistrantName	BIOTRICITY INC.
CY2023Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-0983531
CY2023Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	203 Redwood Shores Parkway
CY2023Q2	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2023Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
CY2023Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
CY2023Q2	dei	City Area Code CityAreaCode	(650)
CY2023Q2	dei	Local Phone Number LocalPhoneNumber	832-1626
CY2023Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q2	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q2	dei	Trading Symbol TradingSymbol	BTCY
CY2023Q2	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8321342	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51433	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	570460	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1512753	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1224137	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2215560	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2337006	usd
CY2023Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	620932	usd
CY2023Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	588599	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	4400678	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	4720202	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	85000	usd
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	85000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	138737	usd
CY2023Q1	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	96344	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20017	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21506	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1499691	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1587492	usd
CY2023Q2	us-gaap	Assets Assets	6144123	usd
CY2023Q1	us-gaap	Assets Assets	6510544	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6563095	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5042476	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	5600051	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4774468	usd
CY2023Q2	BTCY	Term Loan Current TermLoanCurrent	600000	usd
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1984781	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1008216	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	349616	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	335608	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	15097543	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11160768	usd
CY2023Q2	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	870800	usd
CY2023Q1	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	870800	usd
CY2023Q2	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	11629751	usd
CY2023Q1	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	12178809	usd
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	679238	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	759065	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1278405	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1386487	usd
CY2023Q2	us-gaap	Liabilities Liabilities	29555737	usd
CY2023Q1	us-gaap	Liabilities Liabilities	26355929	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51047864	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51047864	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51047864	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51047864	shares
CY2023Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1466718	shares
CY2023Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1466718	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	52514	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	52514	usd
CY2023Q2	BTCY	Common Stock Shares To Be Issued CommonStockSharesToBeIssued	23723	shares
CY2023Q1	BTCY	Common Stock Shares To Be Issued CommonStockSharesToBeIssued	23723	shares
CY2023Q2	BTCY	Shares To Be Issued SharesToBeIssued	24999	usd
CY2023Q1	BTCY	Shares To Be Issued SharesToBeIssued	24999	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	93011897	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	92800717	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-328627	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-152797	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116172404	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-112570825	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-23411614	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-19845385	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6144123	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6510544	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3020765	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2056052	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	1104061	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	830923	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	1916704	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	1225129	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3520215	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4492615	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	712975	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	821176	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	4233190	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	5313791	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2316486	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4088662	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	660512	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	388388	usd
CY2023Q2	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-557219	usd
CY2022Q2	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-50070	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	101452	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-198224	usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	6448	usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-50908	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13435	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3412882	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4776252	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3412882	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4776252	usd
CY2023Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	188697	usd
CY2022Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	248137	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3601579	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5024389	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-175830	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	233004	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3777409	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4791385	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.069
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.069
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.098
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.098
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.069
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.098
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52514582	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52514582	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51440944	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51440944	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52514582	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51440944	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-19845385	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-19845385	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	211180	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-175830	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3412882	usd
CY2023Q2	BTCY	Preferred Stock Dividends PreferredStockDividends	188697	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-23411614	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-23411614	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2144736	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2144736	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	457026	usd
CY2022Q2	BTCY	Preferred Stock Purchased Back Via Cash PreferredStockPurchasedBackViaCash	-285427	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	7500	usd
CY2022Q2	BTCY	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	-30000	usd
CY2022Q2	BTCY	Adjustments To Additional Paid In Capital Issuancof Warrants For Services AdjustmentsToAdditionalPaidInCapitalIssuancofWarrantsForServices	77414	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	149190	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	233004	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4776252	usd
CY2022Q2	BTCY	Preferred Stock Dividends PreferredStockDividends	248137	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-6560418	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-6560418	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-3412882	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-4776252	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	211180	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	149190	usd
CY2022Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	7500	usd
CY2022Q2	BTCY	Issuance Of Warrants For Services IssuanceOfWarrantsForServices	77414	usd
CY2023Q2	us-gaap	Accretion Expense AccretionExpense	557219	usd
CY2022Q2	us-gaap	Accretion Expense AccretionExpense	50070	usd
CY2023Q2	BTCY	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	101452	usd
CY2022Q2	BTCY	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-198224	usd
CY2023Q2	BTCY	Gain Loss Upon Convertible Promissory Notes Conversion And Redemption GainLossUponConvertiblePromissoryNotesConversionAndRedemption	-6448	usd
CY2022Q2	BTCY	Gain Loss Upon Convertible Promissory Notes Conversion And Redemption GainLossUponConvertiblePromissoryNotesConversionAndRedemption	50908	usd
CY2023Q2	us-gaap	Depreciation Depreciation	1489	usd
CY2022Q2	us-gaap	Depreciation Depreciation	1489	usd
CY2023Q2	BTCY	Noncash Lease Expenses NoncashLeaseExpenses	87801	usd
CY2022Q2	BTCY	Noncash Lease Expenses NoncashLeaseExpenses	47547	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	331009	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-179758	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-121446	usd
CY2022Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	588130	usd
CY2023Q2	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	32333	usd
CY2022Q2	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	4312	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1072871	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	567200	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1832118	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4039394	usd
CY2022Q2	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock	328904	usd
CY2022Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	12500	usd
CY2023Q2	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	855538	usd
CY2023Q2	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	479656	usd
CY2023Q2	BTCY	Repayments Of Preferred Stock Dividend RepaymentsOfPreferredStockDividend	6049	usd
CY2022Q2	BTCY	Repayments Of Preferred Stock Dividend RepaymentsOfPreferredStockDividend	516817	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1329145	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-833221	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-502973	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4872615	usd
CY2023Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-16054	usd
CY2022Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13660	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	570460	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12066929	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	51433	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7207974	usd
CY2023Q2	us-gaap	Interest Paid Net InterestPaidNet	258689	usd
CY2022Q2	us-gaap	Interest Paid Net InterestPaidNet	239291	usd
CY2023Q2	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_zxyCODpV7YLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_82C_zxOAhkZ0hUA">NATURE OF OPERATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biotricity Inc. (the “Company”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014, under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over on February 2, 2016.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both the Company and iMedical are engaged in research and development activities within the remote monitoring segment of preventative care. They are focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted to building and commercializing an ecosystem of technologies that enable access to this market.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116172404	usd
CY2023Q2	BTCY	Working Capital Deficiency WorkingCapitalDeficiency	10696865	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	11375690	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	14545805	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	11756563	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1476121	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2355318	usd
CY2023Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	855538	usd
CY2023Q2	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	479656	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3020765	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2056052	usd
CY2023Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1176941	usd
CY2023Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1186735	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1038619	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1150271	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2215560	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2337006	usd
CY2023Q2	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zrrTEdKzw6H5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_867_zDKayQk4BBXd">Significant accounting estimates and assumptions</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the condensed consolidated financial statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair value of stock options</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair value of warrants</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair value of derivative liabilities</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Functional currency</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Useful life of property and equipment</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>BIOTRICITY INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>JUNE 30, 2023 (Unaudited)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Expressed in US dollars)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Provisions</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contingencies</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Inventory obsolescence</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Income and other taxes</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the consolidated balance sheets, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Company’s future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Company’s income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Incremental borrowing rate for lease</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The determination of the Company’s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>BIOTRICITY INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>JUNE 30, 2023 (Unaudited)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Expressed in US dollars)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1984781	usd
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	679238	usd
CY2023Q2	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	2664019	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1008216	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	759065	usd
CY2023Q1	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	1767281	usd
CY2021Q4	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1574068	usd
CY2021Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1042149	usd
CY2023Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	50942	usd
CY2022Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	50070	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	364000	usd
CY2023Q2	us-gaap	Interest Payable Current InterestPayableCurrent	547714	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	239614	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	57536	shares
CY2023Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4173567	usd
CY2023Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	3435123	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2389528	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1607353	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6563095	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5042476	usd
CY2023Q2	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	490964	usd
CY2023Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	446771	usd
CY2023Q2	us-gaap	Adjustment For Amortization AdjustmentForAmortization	15836	usd
CY2023Q2	us-gaap	Line Of Credit Facility Revolving Credit Conversion To Term Loan Description LineOfCreditFacilityRevolvingCreditConversionToTermLoanDescription	In assigning the selling accounts receivables to the revolving loan lender, the Company is receiving 85% of their value as an advance of its regular collection of those receivables, limited to $1.2 million in financing, and expects to receive the remaining balance as part of normal collection activities. The inventory financing provided by this facility was limited to the lower of $0.3 million, or a 40% maximum of inventory balances. The Revolving Facility was accounted for as a secured borrowing. As of June 30, 2023, the Company had drawn $721,214 in accounts receivable financing and $300,000 in inventory financing with aggregate principal outstanding of $1,021,214.
CY2023Q2	us-gaap	Financing Receivable Revolving Converted To Term Loan FinancingReceivableRevolvingConvertedToTermLoan	1200000	usd
CY2023Q2	us-gaap	Line Of Credit Facility Capacity Available For Trade Purchases LineOfCreditFacilityCapacityAvailableForTradePurchases	300000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	721214	usd
CY2023Q2	us-gaap	Line Of Credit Facility Capacity Available For Trade Purchases LineOfCreditFacilityCapacityAvailableForTradePurchases	300000	usd
CY2023Q2	us-gaap	Line Of Credit Facility Annual Principal Payment LineOfCreditFacilityAnnualPrincipalPayment	1021214	usd
CY2023Q2	us-gaap	Interest Expense Other InterestExpenseOther	45217	usd
CY2023Q2	us-gaap	Loan Processing Fee LoanProcessingFee	5099	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	159270	usd
CY2022Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	31414	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	12400000	usd
CY2021Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2026-12-21
CY2021Q4	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.105	pure
CY2021Q4	us-gaap	Debt Instrument Date Of First Required Payment1 DebtInstrumentDateOfFirstRequiredPayment1	2022-02-15
CY2021Q4	us-gaap	Debt Instrument Payment Terms DebtInstrumentPaymentTerms	Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. Prepayment of amounts owing under the Credit Agreement are allowed under prescribed circumstances.
CY2021Q4	BTCY	Origination Fee Amount OriginationFeeAmount	120000	usd
CY2021Q4	BTCY	Exit Fees ExitFees	600000	usd
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	193437	usd
CY2021Q4	us-gaap	Professional Fees ProfessionalFees	48484	usd
CY2021Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	144953	usd
CY2021Q4	us-gaap	Proceeds From Loans ProceedsFromLoans	12000000	usd
CY2021Q4	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	198713	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	759065	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	352402	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-79827	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	195521	usd
CY2022Q2	BTCY	Reduction Due To Preferred Shares Redeemed ReductionDueToPreferredSharesRedeemed	-10605	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	679238	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	537318	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51047864	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51047864	shares
CY2023Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1466718	shares
CY2023Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1466718	shares
CY2023Q2	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	There is also one share of the Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement and outstanding as at June 30, 2023 and March 31, 2023
CY2023Q2	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1.10	pure
CY2022Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4167	shares
CY2022Q2	us-gaap	Stock Issued1 StockIssued1	7500	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7843945	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	110000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7733944	shares
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1278405	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1386487	usd
CY2023Q2	us-gaap	Proceeds From Lease Payments ProceedsFromLeasePayments	141105	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.47
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.77
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0385	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0300	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0301	pure
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.171	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.093	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.195	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.384
CY2023Q2	BTCY	Expected Forfeiture Attrition Rates ExpectedForfeitureAttritionRates	0.0000	pure
CY2022Q2	BTCY	Expected Forfeiture Attrition Rates ExpectedForfeitureAttritionRates	0.0000	pure
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.114	pure
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.114	pure
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y5M1D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M1D
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1587492	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1242700	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	87801	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	50531	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1499691	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1192169	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1722095	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1330338	usd
CY2023Q2	BTCY	Operating Lease Repayment And Interest Accretion OperatingLeaseRepaymentAndInterestAccretion	94074	usd
CY2022Q2	BTCY	Operating Lease Repayment And Interest Accretion OperatingLeaseRepaymentAndInterestAccretion	49510	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1628021	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1280828	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	349616	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	335608	usd
CY2022Q2	us-gaap	Proceeds From Lease Payments ProceedsFromLeasePayments	86279	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	253109	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	552293	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	600288	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	565359	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1971049	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	343028	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1628021	usd
CY2023Q2	us-gaap	Depreciation Depreciation	1489	usd
CY2022Q2	us-gaap	Depreciation Depreciation	1489	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29767	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29767	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8261	usd
CY2023Q2	us-gaap	Depreciation Depreciation	1489	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9750	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21506	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20017	usd

Files In Submission

Name	View Source	Status
btcy-20230630_cal.xml	Edgar Link	unprocessable
btcy-20230630_pre.xml	Edgar Link	unprocessable
0001493152-23-028510-index-headers.html	Edgar Link	pending
0001493152-23-028510-index.html	Edgar Link	pending
0001493152-23-028510.txt	Edgar Link	pending
0001493152-23-028510-xbrl.zip	Edgar Link	pending
btcy-20230630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
btcy-20230630_def.xml	Edgar Link	unprocessable
btcy-20230630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BTCY
BIOTRICITY INC. Stock $btcy

2023 Q3 Form 10-Q Financial Statement

#000149315223028510 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTCY BIOTRICITY INC. Stock $btcy

2023 Q3 Form 10-Q Financial Statement

#000149315223028510 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTCY
BIOTRICITY INC. Stock $btcy